Court Denies Renovaro Motion for an Expedited Trial in July

Rhea-AI Summary

The Delaware Court of Chancery has denied Renovaro's (RENB) request for an expedited trial in July against Predictive Oncology (NASDAQ: POAI), citing RENB's delay in filing their action. The Court has instead scheduled the trial for November 12-13, 2025. POAI, an AI-driven drug discovery company, strongly maintains that RENB's claims are based on inaccurate allegations and lack merit. The company has expressed its commitment to defending its rights and looks forward to presenting its case in court.

Positive

• Court denied opponent's request for expedited trial, giving POAI more preparation time

Negative

• Ongoing legal dispute with Renovaro could result in additional legal expenses and management distraction

PITTSBURGH, May 27, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, today issued the following statement regarding its dispute with Renovaro, Inc.

Contrary to a press release issued by RENB, the Delaware Court of Chancery recently rejected RENB’s request for an expedited, two-day trial in July. The Court reached this decision citing RENB’s delay in bringing its action. 

POAI fully intends to protect its rights and defend against the claims asserted by RENB that are premised on inaccurate allegations and lack any merit. The Court has scheduled trial for November 12-13, 2025.

POAI looks forward to its day in Court. 

About Predictive Oncology

Predictive Oncology is on the cutting edge of the rapidly growing use of artificial intelligence and machine learning to expedite early drug discovery and enable drug development for the benefit of cancer patients worldwide. The company’s scientifically validated AI platform, PEDAL, is able to predict with 92% accuracy if a tumor sample will respond to a certain drug compound, allowing for a more informed selection of drug/tumor type combinations for subsequent in-vitro testing. Together with the company’s vast biobank of more than 150,000 assay-capable heterogenous human tumor samples, Predictive Oncology offers its academic and industry partners one of the industry’s broadest AI-based drug discovery solutions, further complimented by its wholly owned CLIA laboratory facility. Predictive Oncology is headquartered in Pittsburgh, PA.

Investor Relations Contact:
Mike Moyer
LifeSci Advisors, LLC
mmoyer@lifesciadvisors.com

Forward-Looking Statements

Certain statements made in this press release are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward- looking statements reflect Predictive Oncology’s current expectations and projections about future events and are subject to substantial risks, uncertainties and assumptions about Predictive Oncology’s operations and the investments Predictive Oncology makes. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, future revenue and financial performance, projected costs, prospects, changes in management, plans and objectives of management are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “would,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Predictive Oncology’s actual future performance may materially differ from that contemplated by the forward-looking statements as a result of a variety of factors including, among other things, factors discussed under the heading “Risk Factors” in Predictive Oncology’s filings with the SEC. Except as expressly required by law, Predictive Oncology disclaims any intent or obligation to update these forward-looking statements. Predictive Oncology does not give any assurance that Predictive Oncology will achieve its expectations described in this press release.

FAQ

What was the Delaware Court's decision regarding POAI vs Renovaro trial date?

The Delaware Court of Chancery denied Renovaro's request for an expedited July trial and scheduled the trial for November 12-13, 2025.

Why did the Court deny Renovaro's request for an expedited trial against POAI?

The Court denied the request citing Renovaro's delay in bringing its action.

What is Predictive Oncology's (POAI) stance on Renovaro's claims?

POAI states that Renovaro's claims are premised on inaccurate allegations, lack merit, and the company intends to fully defend against these claims.

When is the trial between POAI and Renovaro scheduled?

The trial is scheduled for November 12-13, 2025 in the Delaware Court of Chancery.